Statins Combined with AAV8-TBG-LOX-1 Reduce the Vascular Lipid-driven Inflammatory Response and Inhibit Atherosclerosis

• Published in: Current medical science 2024-12, Vol.44 (6), p.1097-1102
• Main Authors: Zhou, Wen-ping, Fan, Xin-rui, Li, Song-hai, Zeng, Zhuang-lin, Wei, Yu-miao
• Format: Article
• Language: English
• Subjects: Animals; Apolipoproteins E - genetics; Apolipoproteins E - metabolism; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - metabolism; Dependovirus - genetics; Disease Models, Animal; Hepatocytes - drug effects; Hepatocytes - metabolism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Inflammation - genetics; Inflammation - metabolism; Inflammation and Cardiovascular Disease; Lipid Metabolism - drug effects; Lipoproteins, LDL - metabolism; Liver - metabolism; Male; Medicine; Medicine & Public Health; Mice; Mice, Inbred C57BL; Mice, Knockout; Original Article; Scavenger Receptors, Class E - genetics; Scavenger Receptors, Class E - metabolism
• ISSN: 2096-5230; 2523-899X; 2523-899X
• DOI: 10.1007/s11596-024-2954-3

Objective Imbalances in liver lipid metabolism and inflammatory reactions driven by oxidized lipid deposition in blood vessels constitute the core of atherosclerosis. Insufficient degradation of cholesterol in the liver promotes oxidative modification of lipid particles and their deposition on the blood vessel wall in the peripheral circulation. The blood vessel wall engulfs and processes oxidized low-density lipoprotein (Ox-LDL) as foreign matter through pattern recognition receptors, ultimately forming lipid-encapsulated plaques. Among them, endothelial cell oxidized low density lipoprotein receptor 1 (LOX1) phagocytosis is an important link in initiating and promoting this mechanism, and hepatocytes, which are the core of lipid metabolism, are unable to process oxidized lipid particles because of the lack of receptors for the uptake of Ox-LDL. The objective of this study was to investigate whether continuous clearance of Ox-LDL through the liver metabolic pathway could provide better protection against statins therapy. Methods This study used statins combined with an adeno-associated virus (AAV8-TBG-LOX-1) liver-specific transfection system developed by our research group, in which statins reduced the level of LDL and promoted the ectopic expression of LOX-1 in hepatocytes to clear the continuous production of Ox-LDL. An ApoE knockout mouse model was used to study the effects of virus transfection and liver uptake and degradation of Ox-LDL. Laser confocal detection, Oil red staining and immunofluorescence staining were used to observe the effects of combined therapy on anti-atherosclerotic lesions. Results Laser confocal microscopy revealed that the recombinant viral vector AAV8-TBG-LOX-1 could specifically transfect hepatocytes and express LOX-1, which mediate hepatocyte phagocytosis and clearance of Ox-LDL. Oil red O staining of the aorta and valvular ring suggested that statins combined with AAV8-TBG-LOX-1 significantly inhibited atherosclerotic lesions. Tissue immunofluorescence staining suggested that statins could reduce the aggregation of macrophages in plaques and that combined therapy could further reduce the aggregation of macrophages in plaques. Conclusion Statins combined with AAV8-TBG-LOX-1 can alleviate the inflammatory response driven by lipids in the vascular wall, reduce the deposition of macrophages in plaques and inhibit atherosclerosis.